Avacta Group has completed a placing and subscription
Avacta Group Plc has raised US$7.15 million to continue developing next generation cancer therapies.
Avacta’s mission is to shape the future of medicine by developing safe and efficacious drugs and powerful research and diagnostic tools. Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumor-targeted chemotherapy. With this approach, the company aims to address the lack of a durable response to current immunotherapies experienced by most patients.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as financial advisor and broker, assisting Avacta’s management team and shareholders all the way from the start to the successful completion of the fundraising. During this process, the team initiated and advised on many aspects, including, among others, securing pre-commitments from both existing and new institutional investors, deal structuring, document preparation and the fundraise pricing and sizing.
Talk to the deal team
Aenza S.A.A. has completed a follow-on
Aenza S.A.A. has completed af follow-on to prepay part of a recently renegotiated bridge loan.Learn more
move UP has been acquired by Acture B.V.
move UP Gesellschaft für Gesundheitsmanagement mbH, an innovative provider of holistic corporate health management solutions, has been acquired by Acture B.V., a leader in welfare management. This acquisition represents a major step in Acture’s plans to expand into the German corporate health management sector.Learn more
Pampa Camarones has completed an IPO
Pampa Camarones SpA has successfully raised US$5 million through its stock market debut on ScaleX (Santiago Venture Exchange). These funds will be used to extend the mine life and incorporate the high-grade polymetallic project, Ciclón Exploradora.Learn more